Awaiting development: Guidance and quality standards

Showing 91 to 100 of 344

Guidance and quality standards awaiting development
Title	Type
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma [ID6527]	Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]	Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]	Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]	Technology appraisal guidance
Efzimfotase alfa for treating hypophosphatasia [ID6633]	Technology appraisal guidance
Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]	Technology appraisal guidance
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]	Technology appraisal guidance